FDA Issues Warning Over Zerbaxa Label
About Zerbaxa Safety Concern
Currently the U.S. Food and Drug Administration (FDA) is notifying the healthcare field about confusion caused by the drug strength of Zerbaxa displayed on the carton labeling and vial.
According to Medscape, the label displays the strength of each active ingredient, but the product dosage is based on the sum of ingredients. There have been seven cases reported where during dose preparation in pharmacies the wrong amount of drug was administered due to label confusion.
The label has been revised to display the sum of two active ingredients; therefore, Zerbaxa will show 1.5 grams equivalent to ceftolozanae 1 gram and tazobactam 0.5 grams.
Patients and healthcare professionals are urged to report any medication errors that may have occurred or side effects to the FDA MedWatch program.
Description of Zerbaxa's Uses
Information below provided by the FDA:
- Zerbaxa is used in the treatment of infections in urinary tract.
- Zerbaxa is also used in combination with antibacterial drug metronidazole to treat infections in the abdomen.
- Zerbaxa works by killing or inhibiting the growth of bacteria that lead to illness.